GLP1R and diabetes mellitus: In the current study, we highlighted the beneficial impacts of two hypoglycaemic agents—Dapa, a highly potent, reversible, and selective sodium-glucose cotransporter-2 inhibitor, and Lira, a glucagon-like peptide-1 (GLP-1) receptor agonist—as well as their combination on DM-induced renal and hepatic injuries.